The US Food and Drug Administration (FDA) has approved Merck’s Recarbrio injection for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (cIAI).
The US Food and Drug Administration (FDA) has approved Merck’s Recarbrio injection for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (cIAI).